A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Dostarlimab (Primary)
- Indications Anal cancer; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Parotid cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms GARNET
- Sponsors TESARO
- 21 Aug 2019 Planned number of patients changed from 540 to 740.
- 21 Aug 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2023.
- 21 Aug 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Dec 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History